Shah, Mirat

FDA Approval Summary: Pembrolizumab for Neoadjuvant and Adjuvant Treatment of Patients with High-Risk Early-Stage Triple-Negative Breast Cancer

Shah, M., Osgood, C. L., Amatya, A. K., Fiero, M. H., Pierce, W. F., Nair, A., Herz, J., Robertson, K. J., Mixter, B. D., Tang, S., et al. (2022) · Clinical Cancer Research

Breast Cancer Treatment StudiesCancer Immunotherapy and Biomarkers

Cited by 105

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs

Gao, W., Liu, J., Musante, C. J., Zhu, H., Thompson, M., Shah, M., Cao, Y., Ivaturi, V., Conaway, M. R., Bottino, D., et al. (2025) · Clinical Pharmacology & Therapeutics

Statistical Methods in Clinical TrialsPharmaceutical studies and practices

Cited by 2